...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Arthroscopy: the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association >Concentrated Bone Marrow Aspirate May Decrease Postoperative Cyst Occurrence Rate in Autologous Osteochondral Transplantation for Osteochondral Lesions of the Talus
【24h】

Concentrated Bone Marrow Aspirate May Decrease Postoperative Cyst Occurrence Rate in Autologous Osteochondral Transplantation for Osteochondral Lesions of the Talus

机译：浓骨髓抽吸物可能会降低术后骨质骨质骨质骨质病变的自体骨质色神经移植中的术后囊肿发生率

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: To clarify if the use of concentrated bone marrow aspirate (CBMA) would affect both postoperative functional outcomes and magnetic resonance imaging (MRI) outcomes compared with those of autologous osteochondral transplantation (AOT) alone; in addition, to assess the efficacy of CBMA reducing the presence of postoperative cyst formation following AOT in the treatment of osteochondral lesions of the talus. Methods: Fifty-four (92%) of 59 eligible patients who underwent AOT between 2004 and 2008 were retrospectively assessed at a minimum of 5-year follow-up. Twenty-eight patients were treated with AOT and CBMA (AOT/CBMA group) and 26 patients were treated with AOT alone (AOT-alone group). Clinical outcomes were evaluated using the Foot and Ankle Outcome Scores (FAOS) and Short-Form 12 (SF-12) preoperatively and at final follow-up. Postoperative MRI was evaluated with the modified Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) scoring system. Cyst formation was also evaluated on postoperative MRI. Results: The mean FAOS and SF-12 significantly improved in both the AOT/CBMA and AOT-alone groups, but there were no statistical differences between groups in FAOS (80.5 vs 75.5, P = .225) and SF-12 (71.1 vs 69.6, P = .756) at final follow-up. Additionally, there was no difference in the mean MOCART score (80.4 vs 84.3, P = .484); however, AOT/CBMA did result in a statistically lower rate of cyst formation (46.4% vs 76.9%, P = .022). No significant differences were found in the mean postoperative FAOS and SF-12 between patients with and without cysts postoperatively. Conclusions: CBMA reduced postoperative cyst occurrence rate in patients treated with AOT; however, CBMA did not result in significant differences in medium term functional outcomes and MOCART score in patients who underwent AOT.
机译：目的：为了澄清浓缩骨髓抽吸物（CBMA）的使用将影响与单独的自体骨质色神经移植（AOT）相比的术后功能结果和磁共振成像（MRI）结果;此外，为了评估CBMA降低在AOT后术后囊肿形成的存在的疗效治疗术骨的骨质色神节病变之后。方法：在2004年至2008年期间，59名（92％）59名符合条件的患者，在2004年至2008年期间，至少有5年的随访评估。用AOT和CBMA（AOT / CBMA组）对28名患者进行治疗，并单独用AOT（AOT-单独组）处理26名患者。使用脚和踝关节结果评估（粮农组织）和术前和最终的后续后续再次进行评估临床结果。用软骨修复组织（MoCart）评分系统的改性磁共振观察评价术后MRI。还在术后MRI评估囊肿形成。结果：AOT / CBMA和AOT独立群体的平均粮农组织和SF-12显着改善，但粮农组织群体之间没有统计学差异（80.5 Vs 75.5，P = .225）和SF-12（71.1 VS 69.6，p = .756）在最后的后续行动。此外，平均Mocart得分没有差异（80.4 Vs 84.3，p = .484）;然而，AOT / CBMA确实产生统计学上较低的囊肿形成率（46.4％vs 76.9％，p = .022）。在术后和没有囊肿的患者之间的平均术后粮食赛和SF-12中没有发现显着差异。结论：CBMA降低了AOT治疗患者的术后囊肿发生率;然而，CBM​​A没有导致在接受AOT的患者中的中期功能结果和MoCart评分的显着差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号